Impairments in cognitive functions that depend on the prefrontal cortex are a common feature of aging, as well as age-related diseases like Alzheimer's disease (AD). These impairments can reduce quality of life and interfere with daily activities including adherence to medication schedules, thereby resulting in additional effects that impact health in the elderly. A potential strategy to augment prefrontal cortex function is to selectively stimulate basal forebrain projections to the prefrontal cortex, increasing acetylcholine release in the dorsolateral prefrontal cortex and stimulating neuronal mechanisms that underlie normal working memory function. We propose to develop such a strategy in rhesus monkeys, and test its ability to improve cognition. This chemogenetic neuromodulation strategy will use a combination of two viruses: one retrogradely-transported vector containing Cre recombinase into dorsolateral prefrontal cortex and a second Cre-dependent DREADD into basal forebrain. This will selectively target basal forebrain neurons projecting to dorsolateral prefrontal cortex. Once this approach has been tested and validated, we will test whether stimulation of neurons of the primate basal forebrain that project to dorsolateral neocortex is effective in offsetting working memory impairment caused by pharmacological antagonism of acetylcholine. This will provide a critical test in a highly translationally-relevant model of the potential for a neurostimulation intervention, targeted at a discrete neuronal circuit, to improve age-related deficits in cognitive functions of the prefrontal cortex.

Public Health Relevance

Impairments in cognitive functions that depend on the prefrontal cortex are common in aging and in age-related diseases like Alzheimer's disease, and can cause substantial disturbances with daily activities and reduced quality of life. We propose to test a chemogenetic stimulation technology to selectively activate basal forebrain neurons that project to the prefrontal cortex and stimulate its function in working memory, thereby improving working memory and offsetting age-related impairments in this domain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS096936-02
Application #
9390805
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Babcock, Debra J
Project Start
2016-12-01
Project End
2019-11-30
Budget Start
2017-12-01
Budget End
2019-11-30
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Neurosciences
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Upright, Nicholas A; Brookshire, Stephen W; Schnebelen, Wendy et al. (2018) Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys. J Neurosci 38:7969-7975
Halene, Tobias B; Kozlenkov, Alexey; Jiang, Yan et al. (2016) NeuN+ neuronal nuclei in non-human primate prefrontal cortex and subcortical white matter after clozapine exposure. Schizophr Res 170:235-44